RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,574
Mkt Cap
$1.83B
Volume
3.11M
52W High
$7.18
52W Low
$2.80
PE Ratio
-2.33
RXRX Fundamentals
Price
$3.39
Prev Close
$3.46
Open
$3.47
50D MA
$3.42
Beta
2.67
Avg. Volume
14.11M
EPS (Annual)
-$1.44
P/B
1.62
Rev/Employee
$124,468.33
$1,160.13
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. cut their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating for the company in a report on Thursday...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.
Zacks·22h ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed at $3.3 in the latest trading session, marking a -3.23% move from the prior day.
Zacks·2d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Projected to Post Quarterly Earnings on Monday
Recursion Pharmaceuticals (NASDAQ:RXRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...
MarketBeat·4d ago
News Placeholder
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market
Recursion Pharmaceuticals (RXRX) reached $3.5 at the closing of the latest trading day, reflecting a -6.17% change compared to its last close.
Zacks·8d ago
News Placeholder
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Analysts
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings...
MarketBeat·10d ago
News Placeholder
Sumitomo Mitsui Trust Group Inc. Sells 1,244,833 Shares of Recursion Pharmaceuticals, Inc. $RXRX
Sumitomo Mitsui Trust Group Inc. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,221,025 shares of the company's stock after selling...
MarketBeat·14d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $3.6 in the latest trading session, marking a -4% move from the prior day.
Zacks·15d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day.
Zacks·22d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $93,000.00 in Stock
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 30,000 shares of the firm's stock in a transaction dated Tuesday, April 7th. The shares were sold at an...
MarketBeat·23d ago
<
1
2
...
>

Latest RXRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.